Blended solutions case studies

In 2023, a leading China-based biotech firm partnered with ICON to launch a global programme for a key asset. Building on a six-year strategic alliance and success in China, the client expanded into the US and Europe, prioritizing efficiency and cost control. ICON deployed a blended model—FSP in China and the US, and full-service support in Europe — to align with regional needs and strategic goals.

In February 2023, a global biopharma company added ICON to its vendor ecosystem, initially focusing on Clinical Operations. Within a year, ICON grew to represent 20.5% of total FSP resourcing, outperforming expectations and becoming a key partner. ICON has since expanded into multiple services, offering flexible commercial models and scalable support across the client’s evolving needs.

ICON partnered with a leading pharma company to scale its global vaccine program using flexible, custom FSP solutions. By combining dedicated teams with on-demand support, ICON helped expand trial reach, adapt to changing needs, and deliver nearly $10M in annual cost savings.

A top 20 pharma partner adopted a blended model of FSO, FSP, Stand-alone and specialty services to minimise operational costs whilst retaining control and increasing flexibility.

A biopharma partner required support with an FSP model across multiple service areas, seamlessly integrated with an existing FSO partnership.

A 10-year existing FSO partnership was expanded to incorporate a blended model to aid sourcing niche roles across multiple geographies whilst the sponsor maintained greater control of key areas.

Explore the implementation of a dedicated business unit within a 20-year large pharma partnership to facilitate a truly blended solution.

A customised blended model has benefitted a top 10 pharma partner as their organisation has evolved over 13 years.

A Chinese sponsor adopts a blended delivery model to realise cost savings and assume greater autonomy.

A large pharma partner required a blended solutions to support significant upscale across clinical operations, pharmacovigilance and data science.

When a mid-sized biopharmaceutical company was planning pivotal trials for a drug in a rare disease area, it sought
a more transparent, more reliable operating mode.